LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

47.92 -4.16

Overview

Share price change

24h

Current

Min

45.95

Max

47.94

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+7.02% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

409M

3B

Previous open

52.08

Previous close

47.92

News Sentiment

By Acuity

50%

50%

149 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

23 Feb 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 Feb 2026, 22:36 UTC

Earnings

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 Feb 2026, 22:32 UTC

Earnings

Woodside Energy Fiscal Year Net Profit Falls 24%

23 Feb 2026, 23:58 UTC

Market Talk
Earnings

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 Feb 2026, 23:58 UTC

Market Talk
Earnings

Global Energy Roundup: Market Talk

23 Feb 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 Feb 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 Feb 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Crescent Capital Partners Owns 53% of ClearView Wealth

23 Feb 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 Feb 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 Feb 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 Feb 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 Feb 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 Feb 2026, 23:31 UTC

Earnings

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 Feb 2026, 23:31 UTC

Earnings

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 Feb 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 Feb 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 Feb 2026, 23:28 UTC

Earnings

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 Feb 2026, 23:27 UTC

Earnings

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 Feb 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 Feb 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 Feb 2026, 22:31 UTC

Earnings

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 Feb 2026, 22:24 UTC

Earnings

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 Feb 2026, 22:22 UTC

Earnings

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 Feb 2026, 22:22 UTC

Earnings

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 Feb 2026, 22:22 UTC

Earnings

Viva Energy FY Underlying Ebitda A$700.9 Million

23 Feb 2026, 22:22 UTC

Earnings

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 Feb 2026, 22:21 UTC

Earnings

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 Feb 2026, 22:21 UTC

Earnings

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 Feb 2026, 22:20 UTC

Earnings

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

7.02% upside

12 Months Forecast

Average 52 USD  7.02%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

149 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat